Co- development Services.
Matching patients to your targeted therapy.
We specialize in helping companies develop, validate and commercialize companion diagnostics and other in vitro diagnostic (IVD) tests, to help more patients benefit from targeted therapies As your diagnostic partner, we’re here to support your therapeutic launch every step of the way — from discovery to commercialization.
Co- development Pathway.
How ArcherDX develops companion diagnostics
Areas of discovery.
Gene expression signatures.
Viral Integration .
Use our assays.
> 20 products available.
All include design software and team.
Design your own assays.
> 16,000 primers in a single tube.
Powered by our flexible AMP technology
We offer best-in-class panels and ability to assess feasibility in-house or in coordination with certified partners.
Verification and validation.
We are ISO 13485:2016 certified to help with quality assurance and submission planning
The flexibility to offer decentralized testing.
Decentralized tests can help expedite recruiting and patient enrollment, in addition to helping retain clinical study participant s — helping address logistical challenges and cost for study sponsors.
ArcherDX has globally distributed products and CRO relationship s worldwide 3.
Our extensive knowledge in CDx commercialization allows us to support multiple approaches to your launch strategy, helping ensure every biomarker-eligible patient can receive your targeted therapy.
Learn more about our partnerships:.
Collaboration with AstraZeneca to develop Personalized Cancer Monitoring (PCM) assays for MRD.
Collaboration with Bayer to develop companion diagnostic to detect NTRK gene fusions
Archer®MET CDx approval in Japan.
Ready to Start.
Request A Consultation.
2477 55th Street, Suite 202 Tell:.
menu home-icon-silhouette remove-button twitter linkedin-1 facebook-circular-logo right.